The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
iwCLL 2025 | Assessing MRD by cell-free DNA in CLL: results from a real-world series
In this video, Nil Albiol, MD, Hospital Clínic de Barcelona, Barcelona, Spain, briefly discusses the results from a real-world series evaluating the use of cell-free DNA (cfDNA) to assess measurable residual disease (MRD) in patients with chronic lymphocytic leukemia (CLL). Dr Albiol notes that while the assay is feasible, sample collection proved difficult, making this assay challenging to employ in the real-world setting. This interview took place at the biennial International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2025 in Krakow, Poland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
This was a study to assess the feasibility of doing this assay in a real-world setting. And what we observed was that it was not easy, because sample collection was really difficult. But from the 55 patients that we already started with the trial, only 26 have available paired samples with both flow cytometry MRD and cell-free DNA MRD. And we observe a really strong correlation between the cell-free DNA and flow cytometry MRD, but still some discordant results...
This was a study to assess the feasibility of doing this assay in a real-world setting. And what we observed was that it was not easy, because sample collection was really difficult. But from the 55 patients that we already started with the trial, only 26 have available paired samples with both flow cytometry MRD and cell-free DNA MRD. And we observe a really strong correlation between the cell-free DNA and flow cytometry MRD, but still some discordant results. And yes, so overall we think that it’s feasible but it’s not really easy to use it in a real-world setting and there are still some pitfalls that we have to address.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
